“Matador is also excited to announce that its Board of Directors has authorized the repurchase of up to $400 million of Matador ... first quarter of 2025 from $910 per completed lateral ...

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra ...